AACI Commentary

A Professional Development Initiative for Clinical Research Professionals
By Terease S. Waite, PhD, RN, JD, MBE, and Dan T. Vogl, MD, MSCE
December 2023

Collaborating to Reduce Disparities in Cervical Cancer
By Deanna Kepka, PhD, MPH, and B.J. Rimel, MD
November 2023

From Community Outreach to Global Oncology: Perspectives on the 2023 AACI/CCAF Annual Meeting
By Primo N. Lara Jr., MD
October 2023

No Time to Waste: Now is the Time to Advocate for Federal Funding to Support Cancer Research
By Jennifer W. Pegher, MA
September 2023

Aging in Cancer: Preparing for the Silver Oncologic Tsunami
By Andrew Chapman, DO, FACP, FCPP
August 2023

Taking Cancer Clinical Research From Abstract to Reality: Reflections on the 15th Annual AACI CRI Meeting
By Thomas J. George, MD, FACP
July 2023

Beyond the Rainbow Flag: Topics and Outcomes From the First National LGBTQ+ Cancer Symposium
By B.J. Rimel, MD, and Zul Surani
June 2023

A Call for Engagement: AACI Cancer Centers and the National Cancer Plan
By Monica M. Bertagnolli, MD
May 2023

Collaborating to Improve Clinical Trial Activation Timelines
By Tara L. Lin, MD, and Theresa L. Werner, MD
April 2023

Fostering DEI, Providing Culturally Competent Care, and Eliminating the "Minority Tax" at AACI Cancer Centers
By Yolanda Sanchez, PhD
March 2023

Time to Step Outside the Box, Look Back, and PAUSE
By George J. Weiner, MD
February 2023

Best Practices for Maximizing the Value Added By External Advisory Boards
By Anita L. Harrison, MPA
January 2023

Low NCI Paylines and Grant Success Rates Compromise Research Potential
By Roy A. Jensen, MD; Steven K. Libutti, MD, FACS; Thomas J. Lynch, Jr., MD; and Leonidas
C. Platanias, MD, PhD
December 2022

Collaboration is Key to Advancing Precision Medicine in Prostate Cancer Treatment
By Heather Cheng, MD, PhD, and Channing Paller, MD
November 2022

The 2022 AACI/CCAF Annual Meeting: Cancer Center Collaboration Meets Federal Cancer Policy
By Cornelia Ulrich, MS, PhD
October 2022

CTO Staff Retention Task Force Recommendations: Retaining and Recruiting Top Talent Amid the Great Resignation
By Leonidas C. Platanias, MD, PhD
September 2022

Democratizing Artificial Intelligence: Bringing Automated Machine Learning Technologies to Basic, Translational, and Clinical Cancer Researchers
By Dan Theodorescu, MD, PhD, and Jason H. Moore, PhD
August 2022

Enhancing the Diversity of the Cancer Leadership Pipeline
By Caryn Lerman, PhD
July 2022

2022 AACI/AACR Hill Day Highlights Importance of Strong Funding, Continued Advocacy
By Jaren Love
June 2022

Driving Change in Lung Cancer: Cancer Centers Must Ensure That Lung Screening Reaches Those Who Can Benefit Most
By Candace S. Johnson, PhD
May 2022

Marketing and the Physician Outreach Team
By Erin McElwain, MHA, and Heidi Findlay
April 2022
 
Repairing Damage to Clinical Trials Office Staffing
By Kristie Moffett
March 2022

Our Best Defense Against Cancer: Robust Funding is Essential to Continued Research Progress
By Roy A. Jensen, MD
February 2022

Promoting Equity by Design in Cancer Trials
By Barbara E. Bierer, MD, and Timothy Rebbeck, PhD 
January 2022

AACI and the Early Years of the National Cancer Act
By AACI Staff
December 2021

Reflecting on 50 Years of Progress and Looking Ahead to the Future: Highlights of the 2021 AACI/CCAF Annual Meeting
By Robert A. Winn, MD
November 2021

Leadership Development and Diversity in Cancer Centers
By Caryn Lerman, PhD
October 2021

Confronting Delayed Cancer Screening and Cancer Disparities During the COVID-19 Pandemic
By Chyke A. Doubeni, MBBS, MPH
September 2021

Learning From the Pandemic: Reflections on the 13th Annual AACI CRI Meeting
By Theresa L. Werner
August 2021

A “Delicate Dance”: Establishing a Process for Assessing and Endorsing Cancer-Related Policy
By John DeMuro
July 2021

Engaging Advanced Practice Providers in Cancer Clinical Trials
By Christa Braun-Inglis, MS, APRN-Rx, FNP-BC, AOCNP
June 2021

Harnessing Artificial Intelligence and Emerging Technologies to Enhance Cancer Treatment
By Rohit Bhargava, PhD
May 2021

Who Was First? The National Cancer Act of 1971 and the Birth of NCI-Designated Cancer
Centers
By Donald L. Trump, MD, FACP, FASCO and Eric T. Rosenthal
April 2021

The Little State That Could: How West Virginia Became a National Model for COVID-19 Vaccination
By Hannah Hazard-Jenkins, MD, FACS
March 2021

From Pre-Pandemic Politics to a "New Normal": Cancer Policy Priorities for the Biden Presidency
By AACI Staff
February 2021

Sustaining the Use of Telemedicine in Post-Pandemic Cancer Care
By Karen E. Knudsen, MBA, PhD; Cheryl L. Willman, MD; and Robert A. Winn, MD
January 2021

The Broad Relevance of Pediatric Cancer Research
By Charles W. M. Roberts, MD, PhD
December 2020
 
Defining the Role of the CTO Medical Director at AACI Cancer Centers
By CTO Medical Directors' Forum Co-chairs
November 2020 

Confronting Our Twin Pandemics: Reflections on the 2020 AACI/CCAF Annual Meeting 
By Stephen D. Leach, MD
October 2020

Addressing Cancer Health Disparities From the Inside Out
By Ana Maria Lopez, MD, MPH
September 2020

Telemedicine and Cancer Care: Lessons From the COVID-19 Pandemic
By Ruben Mesa, MD
August 2020

Reflections on the 12th Annual AACI CRI Meeting
By Theresa L. Werner, MD
July 2020

Localizing Data to Expand Community Participation in Clinical Trials 
By Robert Winn, MD
June 2020

COVID-19: How AACI’s Corporate Partners Are Helping Cancer Centers and Their Patients Weather the Pandemic
May 2020

COVID-19: What AACI Cancer Centers Are Doing to Mitigate Risks
By AACI Staff
March 2020

Perspectives From the NCI Director: Homecoming and the NCI FY 2020 Budget
By Norman E. Sharpless, MD
February 2020 

Looking Ahead: Forging a Path for 2020 and Beyond
By Jennifer W. Pegher, MA
January 2020